Augurex is at #AMLI2025, Aug 14–17 in Minneapolis! Visit Booth 21 to see how 14-3-3eta advances RA diagnosis & monitoring. Don’t miss the expert-led seminar with Dr. Stanley Naides, Aug 15, 12–1:30 PM, exploring the role of 14-3-3eta in RA management. augurex.com/augurex-to-exh…

We’re excited to share that Mayo Clinic Labs will present a new poster at #AMLI2025 on the value of 14-3-3eta in RA diagnosis, across both early and established disease. We'll see you there! #RA #1433eta #Rheumatology #Biomarkers

Don't miss our seminar at #AMLI2025 in Minneapolis. Join Dr. Stanley Naides on August 15, at 12:30 PM, as he discusses the role of 14-3-3eta in diagnosing and monitoring rheumatoid arthritis. Learn more: amliannualmeeting.softr.app/amli-2025-sche…

September is Rheumatic Disease Awareness Month. Millions live with rheumatic and autoimmune conditions, where early diagnosis is critical. At Augurex, we’re advancing testing to help shorten delays and improve care. #RheumaticDiseaseAwareness #RA #axSpA

1 in 5 people live with chronic pain that affects health, work, and daily life. This #ChronicPainAwareness Month, Augurex stands with patients and supports earlier answers through biomarker testing for #RA and #axSpA. #1433eta #AutoimmuneCare

Augurex will exhibit and present new data at #CCRWest2025 in Huntington Beach, Sep 18–21. Visit Booth 48 & join us Sep 19 at 3:10 PM for posters on RA & axSpA diagnostics featuring our 14-3-3eta biomarker portfolio for earlier diagnosis & better outcomes. augurex.com/augurex-to-exh…

September is #ArthritisAwareness Month. Over 6M Canadians live with arthritis, but earlier testing can change the story. Augurex is working with providers and patients to drive faster diagnosis and better care. #RA #axSpA #1433eta #AutoimmuneCare

Augurex will present new #axSpA data at #ACR25 in Chicago, including an oral presentation by Prof. Raj Sengupta & two posters on the diagnostic utility of 14-3-3eta autoantibodies. Bringing SPINEstat® closer to addressing diagnostic delays in axSpA. augurex.com/augurex-announ…

Augurex and MitogenDx have partnered to expand access to JOINTstat® (14-3-3eta) testing across Canada. This agreement improves access to an innovative biomarker for #RA, enabling earlier diagnosis and ongoing monitoring to help guide patient care. augurex.com/augurex-announ…

Augurex will exhibit and present new data at #ACR2025 in Chicago, Oct 24–29. Don’t miss our oral and poster presentations on the Anti-14-3-3eta Multiplex assay, highlighting the diagnostic value of 14-3-3eta autoantibodies in axSpA. Visit us at Booth 919. augurex.com/augurex-to-exh…

Proud to see AiArthritis spotlight the role of 14-3-3eta testing in their new RA education blog and updated diagnosis page. The feature highlights how the test supports earlier diagnosis, identifies joint damage risk, and tracks treatment response. aiarthritis.org/decoding-bioma…

The FDA has granted Breakthrough Device Designation for SPINEstat®, Augurex’s first-in-class test for #axSpA, recognizing its potential to aid in the clinical decision-making and diagnosis of patients with axSpA. Learn more: augurex.com/augurex-life-s…

We’re excited to see Dr. John Cush spotlight Augurex’s latest ACR 2025 data on the Anti-14-3-3eta Multiplex Test, noting that “the biomarker can distinguish who has axSpA and who does not, a promising step toward a simple diagnostic tool.” 🎥Watch here: youtu.be/EvKv45qybDo

We’re excited to see Dr. John Cush spotlight Augurex’s ACR 2025 data on the Anti-14-3-3eta Multiplex Test, highlighting how it complements HLA-B27 and CRP to improve #axSpA diagnosis and help differentiate axSpA from mechanical back pain. 🎥 youtu.be/X8Sc_3oBSVA

During #PainAwarenessWeek, we recognize those living with chronic pain from autoimmune diseases like #RA and #axSpA. At Augurex, we enable earlier detection and better care with biomarker tests like 14-3-3eta and Anti-14-3-3eta Multiplex, helping prevent long-term damage.

We’re pleased to share that Sonic Reference Laboratory will launch the 14-3-3eta test for #RheumatoidArthritis across the U.S. on Dec 15, 2025. This blood test enables earlier diagnosis, more precise monitoring, and better patient outcomes. Learn more: augurex.com/augurex-life-s…

Excited to see Dr. Norma Biln featured on the Spondylitis.org Spondycast #Podcast discussing how biomarkers & tools like SPINEstat® can help reduce diagnostic delays in axSpA by improving early detection & referral accuracy. Listen here: spondylitis.org/podcasts/episo…

Augurex CEO Neil Klompas joins the Progress, Potential, And Possibilities podcast for the episode “Ending Diagnostic Delays in Autoimmune Conditions” to discuss how SPINEstat® supports earlier, more accurate detection of #axSpA and helps address long diagnostic delays. 🎧 progresspotentialpossibilities.com/podcast/episod…

We’re excited to see the Spondylitis.org Association of America feature Augurex’s latest ACR 2025 data in a new article and eSUN newsletter. The coverage highlights how SPINEstat® (Anti-14-3-3eta Multiplex test) may help improve early axSpA diagnosis & care. spondylitis.org/research-new/n…

Honored to be featured by Moira Gunn of NPR's #BioTechNation as one of the Top 5 JPM interviews. In this special edition, Augurex shares how we’re closing gaps in back pain and axSpA care, where patients often wait 7–10 years for answers. #JPM2026 podcasts.apple.com/us/podcast/you…